Joel F. Martin, PhD, is our President and Chief Executive Officer (CEO), a co-founder, and serves on our Board of Directors. From 2012 to January 2015, Dr. Martin was the President and CEO of Cebix Incorporated, a company that advanced a diabetes drug rapidly through a large, international Phase 2b trial. From 2008 to 2010, Dr. Martin was President and CEO of Altair Therapeutics, a Phase 2 asthma company that was acquired in 2010.
Dr. Martin has extensive venture capital experience and maintains strong connections throughout the venture industry. He was a partner at Forward Ventures from 2001 through 2008, where he led successful investments in neuroscience and cancer companies such as Hypnion, Predix, and Cellective Therapeutics. He was previously an executive-in-residence and associate at Institutional Venture Partners and Avalon Ventures, respectively.
Dr. Martin is a skilled serial entrepreneur. He was the co-founder and CEO of Quantum Dot Corporation (acquired by Invitrogen), a company that pioneered quantum-confined luminescent nanocrystals, arguably the first commercial nanotechnology product. Prior to that, he was the co-founder and CEO of Argonaut Technologies, a publicly traded chemistry automation and solid-phase reagents company, which was acquired by Biotage AB. At Argonaut, he pioneered a new business model, where a consortium of pharmaceutical companies financed product development with non-dilutive capital.
Dr. Martin began his career as assistant professor of radiology at University of California, San Diego (UCSD) where he developed novel digital image processing techniques and invented the first medical device for MRI imaging of the prostate. Dr. Martin earned his Ph.D. in physical chemistry from UCSD and holds MBA and B.S. Chem. Honors degrees from the University of Michigan, Ann Arbor. He did postdoctoral research combining MRI imaging with NMR spectroscopy at IBM. He is currently a member of the advisory boards of the Life Sciences Institute at the University of Michigan and the Rady School of Business at UCSD.
Olivier Laurent, PhD, is our Chief Scientific Officer, having joined the company in July 2015 as our Vice President of Development. Prior to joining Dauntless, Dr. Laurent held senior positions directing drug discovery, development, and production at several pharmaceutical companies.
Dr. Laurent was most recently a leadership team member and the Vice President in charge of CMC at Ambrx from 2013 until the sale of the company in 2015. Dr. Laurent was Director, Protein Science and Target Identification at Pfizer from 2009 to 2013 and Associate Director, Drug Product Formulation and Manufacturing at Pfizer from 2008 to 2009. Prior to Pfizer, Dr. Laurent held drug development positions of increasing responsibility at CovX, a clinical stage biotech company acquired by Pfizer in 2008, as well as Genentech, Bayer, and Aventis (now Sanofi).
Dr. Laurent conducted his graduate work with the French Atomic Agency and received his Ph.D. in Cell Biology from Grenoble University in 1997. He is an Alumni of the Ecole Normale Supérieure of Lyon.
Michelle Mazzoni, PhD, is our Regulatory Affairs and Quality Consultant and has served in this position since the company was founded in May 2015. Prior to joining Dauntless, Dr. Mazzoni held senior positions at multiple pharmaceutical companies where she directed regulatory affairs, quality, nonclinical, and project management activities for early to mid-stage clinical development assets.
Dr. Mazzoni’s past positions include Vice President, Regulatory Affairs and Quality at Cebix Incorporated from 2009 to 2015; Senior Director, Regulatory Affairs at SGX Pharmaceuticals before its acquisition by Eli Lilly; and Senior Director, Regulatory Affairs and Drug Development at TargeGen. Prior to that, she held positions of increasing responsibility at Alliance Pharmaceutical Corp. and Imcor Pharmaceuticals.
Dr. Mazzoni received her bachelor’s degree in Mechanical Engineering from the University of Minnesota Twin Cities and M.S. and Ph.D. degrees in Bioengineering from the University of California, San Diego (UCSD). She also obtained a professional certificate in Regulatory Affairs for the Biomedical Industry from UCSD in 2004.
Mark Daniels is our Director of Clinical Operations and has served in this position since the company was founded in May 2015. Most recently, Mr. Daniels spent 5 years as the Director of Clinical Operations at Cebix Incorporated where he was responsible for leading the C-peptide clinical development program from the first-in-human study to the completion of a large-scale, proof-of-efficacy Phase 2b international study.
Prior to his role at Cebix, Mr. Daniels managed all phases of global clinical development studies at several pharmaceutical companies with a strong emphasis on neurology and oncology including Biogen Idec from 2007 to 2011, and Elan Pharmaceuticals from 2002 to 2007. Mr Daniels also held positions of increasing responsibility at Quintiles, a contract research organization, from 1997 to 2002.
Mr. Daniels received his Bachelor’s of Science degree in Psychobiology from the University of California, Los Angeles in 1997.
Mike has more than 25 years of pharmaceutical development experience, and has focused on clinical-stage product companies, particularly in the oncology and neurology areas. He joined Sofinnova Investments as a General Partner in 1997. Prior to becoming a venture capitalist, Mike worked on 20 clinical products and authored almost 100 papers and books, including an 1,000–page treatise on vaccine design. Mike was the initial investor in: Actelion (SWX: ATLN), InterMune (Nasdaq: ITMN), Anesiva (Nasdaq: ANSV), Orexigen Therapeutics (Nasdaq: OREX), Seattle Genetics (Nasdaq: SGEN), Threshold Pharmaceuticals (Nasdaq: THLD), and Trius Therapeutics (Nasdaq: TSRX), as well as several private companies such as: Alvine, Ascenta and Intellikine (acquired by Millennium/Takeda). He most recently led Sofinnova’s investments in Mirna Therapeutics (Chairman) and Labrys Biologics.
Mike also is the Past Board President of AVAC (AIDS Vaccine Advocacy Coalition) in NYC, a past Advisor to the Bill and Melinda Gates Foundation, a past Strategic Advisor to One World Health, and a Founding Venture Advisory Board member of the IAVI (International AIDS Vaccine Initiative) Innovation Fund. He also serves on the University of Kansas board of IAMI (Institute for the Advancement of Medical Innovation), as well as a Trustee for Washington University in St. Louis. He is also an Adjunct Associate Professor at the University of Kansas in Pharmaceutical Chemistry. Mike has the honor of being the first scientist from the biotechnology industry to be elected a Fellow of the American Association of Pharmaceutical Scientists.
Prior to his venture career, Mike was Group Leader of Drug Delivery at Genentech (1990–97) where his focus was developing new formulations for protein and peptide therapeutics. In 1987 he was part of the founding team of Cytel; as Director of Product Development he was responsible for the company’s early growth to IPO. Before this he was Scientist and Project Team Leader at Syntex Research (Roche). He received his PhD in Physical Chemistry from the University of Toronto in 1981, and completed his post-doctorate work in Bioorganic Chemistry at the University of California, where he was subsequently a faculty member (1981–84).
David joined Sofinnova Investments as an Executive Partner in 2007. He represents Sofinnova Investments as the Chairman of NextCure, and as Director of Antiva Biosciences, Dauntless Pharmaceuticals, and Principia. He also serves as Chairman of Lineagen and as a Director of bioTheranostics. Previously he served as the Chairman of both Trius Therapeutics and Amplimmune, and as a Director of InterMune and Allylix.
Prior to Sofinnova Investments, David spent almost 30 years in industry leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields. David co-founded Salmedix, a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer. In June 2005, he negotiated the acquisition of Salmedix by Cephalon. David also held the positions of Executive Vice President of Dura and President and Chief Executive Officer of Spiros while at Dura Pharmaceuticals, a specialty respiratory pharmaceutical and pulmonary drug delivery company. Earlier, David was also employed as Chief Executive Officer of Corvas International and held senior executive positions with Hybritech.
David received his PhD from Yale University and his BA from Case Western Reserve University.
Nina Kjellson joined Canaan’s healthcare team as a General Partner in the Fall of 2015. She focuses on early-stage investments in biopharmaceuticals and digital health. Current investment themes include therapeutics for serious and underserved conditions such as cancer, autoimmune disease and life-threatening infections; patient/consumer engagement; and IT-enabled transformation of healthcare delivery. She is co-founder and co-chair of ConsumerMed.org, a forum to address the convergence of health care and consumer innovation and serves as a mentor to Blueprint Health, a digital health incubator and Springboard Life Sciences, an accelerator for healthcare companies driven by women entrepreneurs. She is a member of the advisory board for the Oliver Wyman Health Innovation Center.
Current investments include Annum Health, Cidara (CDTX), Dauntless Pharmaceuticals, Eiger Biopharmaceuticals, Lycera Inc., Ocera (OCRX), Paratek (PRTK), Tizona Therapeutics and WellTok. She serves on the boards of Annum, Dauntless, Eiger, Lycera, Ocera, Tizona, and WellTok.
Previous investments include Labrys Biologics (acquired by Teva), Alt12 (acquired by Honest Company), Trius Therapeutics (TSRX; acquired by Cubist), CNS Therapeutics (acquired by Covidien), NovaCardia (acquired by Merck), and Aspreva (ASPV; acquired by Galenica).
Prior to Canaan, Nina was a General Partner at InterWest Partners where she had been investing in healthcare start-ups since 2002. Before InterWest, she was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a health care-focused hedge fund. Nina began her career conducting health policy and survey research with the Kaiser Family Foundation.
Nina was born in Scandinavia and grew-up in the Northeast. Nina received a B.A. in human biology from Stanford University (1997). She makes her home in the Bay Area.
She serves on board of Essential Access Health and the California Leadership Council for the Nature Conservancy.
Ellen is Chief Business Officer for Impel Neuropharma and is responsible for Business and Corporate Development activities and strategy, including aspects of Investor Relations. She brings to Impel nearly 20 years of biopharmaceutical industry experience, including global partnering, asset sourcing and acquisition, financial structuring and leading early-stage company operations, fundraising and board governance. Prior to joining Impel, she served as the Vice President of External Science & Innovation at Allergan, where she was responsible for strategic expansion of the company’s pipeline in a variety of disease areas, including Alzheimer’s disease, Parkinson’s disease and autism. Prior to joining Allergan, Ellen served in financial, strategic, commercial and corporate development executive positions at Kadmon Pharmaceuticals, Bristol-Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank and Abbott Labs. She has her MBA from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College. Ellen also serves on the Board of Directors of GeneCentric Therapeutics and is on the Scientific Advisory Board of the Daedalus Innovation Fund of Weill-Cornell.